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 Abstract 
Based on promising results seen in regenerative therapies for wound healing, this study 
explores the use of delivering stem cells through a fibrin hydrogel for the treatment of emphysema, 
an end stage lung disease. To determine an optimal formulation of the biopolymer fibrin, gene 
expression of lung resident mesenchymal stem cells (LR-MSCs) was studied in three different 
scaffold formulations. In addition, mechanical modeling was completed to correlate any 
uncharacteristic behavior with a change in mechanical properties. The results from the study 
indicated that a 3 mg/mL concentration of fibrinogen with 500U of thrombin may be optimal over 
the currently used concentrations in the Hoffman laboratory at Tufts Cummings School of 
Veterinary medicine; however, additional testing needs to be completed to validate mechanical 
modeling and demonstrate the potency potential of LR-MSCs on secondary cell lines.  
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Chapter 1. Introduction 
 Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in the 
United States (Epidemiology, 2012). Characterized by the inability to fully exhale, and thus 
difficulty in breathing and supplying the body with adequate oxygen, emphysema is a type of 
COPD which is often terminal. Medications such as bronchodilators, steroids, or antibiotics may 
be prescribed to ease the difficulty of breathing; however, the only long term solution is a lung 
transplant. The limited availability of transplants, along with donor compatibility, and high 
rejection rate make lung transplants extremely difficult and costly.  
As a result, the area of designing stem cell therapies for COPD has become increasingly 
popular. A commonly used cell type in regenerative therapies is Mesenchymal Stem Cells (MSCs). 
MSCs are readily available and can be derived from various parts of the body. Additionally, they 
are particularly known for their ability to signal adjacent cells through the secretion of unique 
cytokines as a mode of treatment. Although MSCs derived from bone-marrow (BM-MSCs) have 
shown potential for regenerative effects, recent isolation of MSCs from adult lung parenchyma has 
shown better retention in the lung compared to BM-MSCs. Current stem cell therapies for COPD 
using lung resident MSCs (LR-MSCs) encapsulated in a fibrinogen (3.2%)-fibronectin (0.2%) 
thrombin hydrogel are being explored through ovine emphysema models at Tufts Cummings 
School of Veterinary Medicine. However, there are still many questions about the effects of the 
scaffold on cell signaling for this particular design.  
The purpose of this project was to strategically design a biological scaffold for pulmonary 
regeneration. The potential for such a scaffold will not only increase the likelihood of an effective 
therapy for COPD patients, but it can also provide insights for which scaffold formulations best 
induce gene expression profiles in LR-MSCs that correlate with restoration of pulmonary function.   
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The group chose to pursue a fibrin scaffold and focused on observing changes in gene expression 
of LR-MSCs within various scaffold groups as well as mechanical modeling to predict whether 
the fibrin scaffold could withstand or mimic the properties seen in alveolar lung tissue. 
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Chapter 2. Literature Review 
2.1 The Respiratory System 
 The process of breathing in and out is essential for supplying oxygen to the trillions of cells 
within the human body. On average, the human respiratory system brings 7L of air/min into the 
two lungs. Respiration, the process of removing carbon dioxide from the blood and replacing it 
with oxygen occurs in two stages, gas exchange and cellular respiration. Gas exchange involves 
the transfer of carbon dioxide and oxygen between the atmosphere and the blood through the 
pulmonary cavities. The second stage breaks down oxygen by a series of metabolic reactions which 
release carbon dioxide and energy. This cycle is then repeated, as oxygen is required to provide 
the initiation of cellular respiration. The respiratory system has many important components that 
allow it to function properly, such as muscles and an airtight chest wall; however, the lungs are a 
major component in the system (Rhoades and Bell, 2009). 
2.1.1 Lung Structure 
The human body contains two lungs, each with numerous lobes. The trachea and first 
sixteen generations of airway branches are called the conducting zone; this area is responsible for 
warming and humidifying the air, distributing the air evenly to deeper parts of the lungs and 
serving as part  of  the  body’s  defense  system  against  foreign  material.  The  last  seven  generations  
include the respiratory zone, which is home to alveolar ducts and 300-500 million alveoli with an 
internal surface area of 75m2 (Rhoades and Bell, 2009). This zone is responsible for the gas 
exchange and pulmonary circulation. This capillary network has been viewed as the most extensive 
in the body. The respiratory system is outlined in Figure 1. 
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Figure 1. (A) Labelled diagram of respiratory system. (B) Enlarged view of the alveoli and capillaries in the lung. (C) 
Process  of  gas  exchange  between  capillaries  and  alveoli.  (“The  Respiratory  System,”  2012) 
The mechanics of breathing are controlled by the diaphragm and pressure. Contraction of 
the diaphragm allows the airtight thoracic cavity to expand and thus inflate the lungs. Although 
the diaphragm is an essential part in breathing, the process of inflation and deflation of the lungs 
could not be completed without proper pressure-volume relationships. Because the thoracic cavity 
is airtight, an increase in volume causes a decrease in pleural pressure, or the pressure in the pleural 
space between the lungs and chest wall. During normal inspiration, pleural pressure remains 
negative because the elastic recoil of the lung acts like a spring causing equal and opposite forces 
between the lung and chest wall. The ability of the lungs to expand and retract is due to the collagen 
and elastin fibers which form a mesh around the alveolar walls. Elastin fibers can be stretched to 
nearly double their length, while collagen fibers resist stretch to limit lung expansion. A lung that 
has lost its elastic recoil becomes easy to inflate but hard to deflate. In order to maintain 
compliance, the lungs must sustain a constant surface tension throughout changes in pressure and 
volume. The moist alveolar membrane causes surface tension because water molecules are more 
strongly attached than air molecules which results in an inwardly directed force that can cause 
alveoli to collapse. To compensate, the alveolar lining is coated with pulmonary surfactant, a liquid 
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which lowers surface tension at the interface and changes the surface tension depending on the 
alveolar diameter. This unique fluid contains dipalmitoylphosphatidylcholine (DPPC), an agent 
that makes it possible for alveoli of different sizes to survive at low lung volumes (Hoehm and 
Marieb, 2013; Rhoades and Bell, 2009). 
Although there are over 40 types of cells in the lung, two unique cells are alveolar type I 
and type II cells. Alveolar type II cells, also called type II pneumocytes, are responsible for the 
synthesis of surfactant. These cells are rich in mitochondria and contain electron-dense lamellar 
inclusion bodies which are thought to be the storage sites for surfactant. Although the ratio of type 
I to type II cells is about 1:1, type I cells occupy about two-thirds of the alveolar surface (Rhoades 
and Bell, 2009).   
2.1.2 Lung Biomechanics 
 Because the lungs are constantly inhaling or exhaling, the tissues are always subjected to 
tensile stress. This stress, also known as prestress, is a result of transpulmonary pressure. It is 
distributed throughout the lung by interaction of the extracellular matrix (ECM) and the collagen 
in the lung. Collagen is the main load-bearing component of all connective tissue; therefore, it is 
responsible for transferring stresses to the ECM. Mechanical testing has found the Young’s  
modulus of an alveolar wall to be approximately 5 kPa (Suki et al., 2005).  
 The forces within the lung depend on lung compliance and the current volume of the lung. 
Since lung volume increases with inhalation, lung compliance also increases, thus increasing the 
forces within the lungs. Calculations based on the compliance equation, C = V / P, where V= 
volume and P= pressure, revealed a maximum force of 7.68 N and a resting force of 5.11 N over 
a 9.60 cm2 area.  These  values  are  consistent  with  Mijailovich  et  al.’s  (1994)  study  in  a  rabbit  lung.  
Mijailovich et al. measured a maximum force of approximately 6 N.  
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 In emphysema patients, both forces within the lung and Young’s  modulus  are  affected.  
Due to the inability to fully exhale, there are mechanical changes in the alveolar wall. This 
consequently causes the lung to respond to changes in deformation differently. Overall, this could 
lead to deviations in the way the ECM interacts with other molecules (Suki et al., 2005).  
2.1.3 Measuring Lung Function 
 Pulmonary function tests may be used to quantify whether the lung is functioning properly. 
Spirometry is a procedure used to measure the volume of air inspired or expired by the lungs. 
These devices can be used to measure the maximum amount of air in the lung (vital capacity), the 
volume of air remaining in the lungs after expiration (functional residual capacity), and the volume 
of air when expiration is performed rapidly (force vital capacity) (Townsend, 2011). Figure 2 
shows how results of spirometry are quantified so that they can be compared for patients based on 
expected values given height, age and gender. Generally, a healthy result is >80% of the predicted 
value, while abnormal results are 60-79% for mild lung dysfunction, 40-59% for moderate lung 
dysfunction, and <40% for severe lung dysfunction (Boriello et al., 2012). 
 
Figure 2. Flow vs. Volume graphs can be used to determine several values such as FVC, FEV1, FEV1/FVC and PEF. 
Based on the curve result, spirometry can be used to classify types of lung diseases (Boriello et al., 2012). 
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2.1.4 Respiratory Disease 
According to the Center for Disease Control and Prevention, 10.1 million (4.4%) adults in 
the U.S. have been diagnosed with chronic bronchitis within the past year, and 4.7 million (2.0%) 
have been diagnosed with emphysema (CDC, 2013), the prevalence data are shown in Figure 3. 
Chronic obstructive pulmonary disease (COPD) constitutes a group of lung diseases all caused by 
the obstruction of airways which impacts breathing ability; in fact, COPD is the third leading cause 
of death in the U.S. and is predicted to cost about $42.6 billion, including $26.7 billion in direct 
health care expenditures, $8.0 billion in indirect morbidity costs, and $7.9 billion in indirect 
mortality costs (Epidemiology, 2012).  
 
Figure 3. Age adjusted prevalence (%) of adults who answered yes to "Have you ever been told you have COPD, 
emphysema or chronic bronchitis?" Sources for data taken in 2011 from Centers for Disease Control and Prevention, 
National Center for Health Statistics, and behavioral Risk Factor Surveillance System (CDC, 2013).  
Obstruction of the lungs is characterized in three ways, excess mucus, airway narrowing, 
or airway collapse during expiration. Subdivisions of COPD include bronchitis, asthma, and 
emphysema which are all characterized by the slowing down of movement during expiration or 
the inability for those affected to empty their lungs. Inflammation in one or more bronchi causes 
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bronchitis and excessive mucus production. The over-distension and loss of elastic recoil in the 
lungs causes emphysema while spasmodic contractions of the smooth muscle on the bronchi cause 
asthma. Altogether, these conditions result in a decrease in forced vital capacity and forced 
expiratory volume. Bronchitis and emphysema often affect the same patient as the mucus caused 
by bronchitis leads to a severe cough which stretches the lungs and decreases their ability to recoil. 
The effect of emphysema at the microscale can be seen in histological samples of normal and 
diseased lung tissue (Figure 4). As shown in the images, the normal lung tissue shows a dense 
alveolar network while the emphysema model shows larger alveoli diameters with reduced alveoli 
cells which supports the problem seen in emphysema in that the lungs are difficult to empty 
because of these large air pockets (Schleede et al., 2012). If the disease progresses patients 
typically experience hypoxemia and hypercapnia which eventually cause right-heart failure.  
 
Figure 4. Histological sections in experimental emphysema model give a representation of the typical problems seen in 
diseased lung tissue at the microscopic level (Schleede et al., 2012). 
9 
 
2.1.5 Treatment Options 
Currently, this end-stage lung disease has a limited number of treatment options. In certain 
cases, doctors may prescribe drugs to ease symptoms. Bronchodilators which work by opening the 
airways to permit more efficient oxygen exchange in patients with excess mucus can be divided 
into   three   different   categories:   “sympathomimetics (isoproterenol, metaproterenol, terbutaline, 
albuterol), which can be inhaled, taken by mouth, or injected; parasympathomimetics (atropine); 
and  methylxanthines  (theophylline),  which  may  be  administered  intravenously,  orally,  or  rectally” 
(Swartout-Corbeil et al., 2011). Other drugs for treating emphysema include steroids 
(beclomethasone, dexamethasone, triamcinolone, flunisolide) which lower tissue inflammation, 
antibiotics which may help fight lung infections, and expectorants which loosen mucus in the 
lungs. An alternative therapy which can increase survival rate in emphysema patients is oxygen 
therapy which can be administered by portable oxygen tanks but it must be used 18-24 hours every 
day (Swartout-Corbeil et al., 2011). Surgery may be beneficial for removing parts of the diseased 
lung to allow for lung volume reduction. Another recently proposed method for lung volume 
reduction is the use of a polymer sealant to close off damaged areas of the lungs; however, this 
treatment is still under investigation in clinical trials (Ingenito, 2010). Unfortunately, the closest 
long term solution to “curing” the disease is a lung transplant, which is not only limited in 
availability but also poses the risk of rejection, along with a mere 50% five year survival rate and 
lifelong immune-suppression. Because of the overwhelming need for a new treatment option, 
scientists have been exploring new therapies using the idea of tissue regeneration to repair 
damaged lungs. 
2.2 Therapies for Lung Regeneration 
 The regeneration approach originates from the idea that an entire limb, organ, or tissue in 
the body can be entirely re-grown. The biological process to undergo such a task is quite 
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complicated as it involves tissue remodeling, reprogramming genes, differentiation, proliferation, 
and migration of stem cells to the site of interest. Despite the complicated process, stem cell 
therapy has real potential for future treatment options, not only of the lung but of any body part. 
2.2.1 Mesenchymal stem cells 
 Although there are many types of stem cells, the most widely used is the mesenchymal 
stem cell (MSC). These multipotent stem cells are readily available, have multi-lineage 
differentiation potential, secrete large amounts of cytokines and have been shown to have 
immunosuppressive properties (Weiss, 2010). Originally termed Colony-Forming Unit-
Fibroblasts (CFU-F) after demonstrating self-renewal capabilities in bone marrow cells during the 
1960s, these cells were later labeled  “mesenchymal  stem  cells” in 1991 (Collins and Thebaud, 
2013). Numerous in vitro and in vivo studies have demonstrated benefits from MSC 
transplantations; however, despite the promising outlook, few MSCs attach to the target area in 
vivo or they cleared  by  the  body’s  immune  response  before  the  cell  can  help  heal  the  damaged 
region (Davis et al., 2011).  
2.2.1.1 Characterization 
All MSCs must follow a minimum set of criteria. First, when cultured in a flask under 
standard culturing conditions, MSCs must adhere to the tissue culture plastic. The cells must 
express the surface markers CD105, CD90, and CD73 and should lack expression of the 
hematopoietic markers CD45, CD14 or CD11b, CD34, CD19 or CD79a or HLA-DR. Finally, all 
MSCs must be capable of tri-lineage differentiation into osteogenic, adipogenic, and chondrogenic 
lineages upon in vitro stimulation (Collins and Thebaud, 2013). 
2.2.1.2 Types 
MSCs can be isolated from stromal tissue of many organs, including bone marrow, muscle, 
periosteum, adipose, dermis, and lung. These cells have been reported to show high similarity to 
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other cell types such as perivascular cells and fibroblasts. Perivascular cells (pericytes, PCs) are 
multi-lineage progenitor cells which differentiate in culture to adherent cells with a specific MSC 
phenotype. These similarities suggest that PCs may be the progenitors of MSCs. Because of MSCs 
similarity to other stem cell types, the differences between MSCs derived from various areas of 
the body has become an interest to scientists in regenerative medicine (Collins and Thebaud, 
2013). 
2.2.1.2.1 Bone marrow derived mesenchymal stem cells 
Bone marrow derived mesenchymal stem cells (BM-MSC) were the first type of MSC to 
be discovered. The potential of these cells to differentiate into adipocytes, osteoblasts, 
chondrocytes and other tissues of mesodermal origin has made them extensively analyzed for their 
possible in vivo use (Ricciardi et al., 2012). The cells have been shown to migrate to and remodel 
lung tissue in healing allografts of lung transplant patients; however, when implanted into animal 
models of lung disease, the therapy shows little success (Ingenito et al., 2012). 
2.2.1.2.2 Lung resident mesenchymal stem cells 
Recently, a new line of MSCs has been isolated from adult lung parenchyma. Lung resident 
mesenchymal stem cells (LR-MSCs) have been shown to produce lung-specific basement 
membrane proteins such as collagen IV, laminin, and fibrillin-1 and enhance the growth and 
spreading of epithelial progenitor cells. Furthermore, these cells express greater levels of the 
intracellular adhesion molecule, PDGFRa, and integrin a2, thus causing increased adherence of 
LR-MSCs to endothelial cells (Davis et al., 2011). In vitro, these cells have been observed to 
differentiate into epithelial, endothelial and nerve cells. Furthermore, in vivo studies in a murine 
emphysema model found that LR-MSCs demonstrate greater survival and avoidance of blocking 
antibodies than BM-MSCs after intravenous transplantation. In humans, LR-MSCs exhibited 
12 
 
potential to inhibit T-cell proliferation, thus modulating immune responses (Ingenito et al., 2012; 
Collins and Thebaud, 2013).  
2.2.1.3 Cell Signaling 
The ability for cells to function under abnormal conditions stems from their ability to 
maintain homeostasis. Self-regulation  of   the  body’s   internal  environment   is  greatly  affected  by  
cells ability to communicate with one another in order to respond accordingly to the presented 
variation. Cells have numerous modes of direct and indirect communication. Stem cells in 
particular are known for their ability to communicate using indirect signaling. Most notably, they 
can communicate using paracrine signaling, or by the release of a chemical messenger. Paracrine 
signaling works by the diffusion of a chemical signal across extracellular fluid to a nearby cell 
where it binds with high specificity to cell receptors on the plasma membrane of the receiving cell. 
 MSCs have been shown to serve as an effective therapy for treating lung injury because of 
their capabilities to signal adjacent cells. Several studies have demonstrated MSCs ability to 
modulate the immune system by releasing immunosuppressive factors such as prostagladin E-2 
(PGE-2) in response to dendritic cells, T and B cells, and neutrophils. More importantly, LR-MSCs 
have shown the ability to secrete growth factors such as vascular endothelial growth factor 
(VEGF), keratinocyte growth factor (KGF), and hepatocyte growth factor (HGF) which have 
cytoprotective and repair properties (Fitzgerald et al., 2001). Although it is unknown which 
cytokines impact injured cells the most, the importance of creating a therapy that allows for or 
encourages cell signaling is evident for MSCs. 
 This project will investigate the effects of various cell scaffolds on the gene expression 
profiles of LR-MSCs. Seven gene expression candidates were carefully chosen for analysis, and 
are described below (two are of the FGF type). 
13 
 
2.2.1.3.1 Vascular Endothelial Growth Factor 
 Vascular Endothelial Growth factor (VEGF) plays a role in vascular development, 
specifically during embryogenesis (vasculogenesis) as well as blood-vessel formation 
(angiogenesis). This heparin-binding, dimeric protein also acts as a mitogen for endothelial cells, 
and plays a role in activating and chemo-attracting monocytes. VEGF belongs to a family of 
proteins including VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta-like growth factor 
(PLGF).The ability for VEGF to stimulate endothelial cells to proliferate, migrate, and survive in 
an altered environment has caused increasing interest into how and why cells excrete this factor. 
VEGF-A, a 23 kDa glycoprotein and one of the more common forms of VEGF in humans has five 
different isoforms (Breen, 2007). VEGF-B has been associated with regulation of extracellular 
matrix degradation, cell adhesion and migration. VEGF mRNA expression studies in the heart, 
placenta, ovary, small intestine, and the thyroid gland suggest that VEGF-C may play a role in 
proliferation of blood and lymphatic vascular endothelial cells. Platelet-derived growth factor-B, 
epidermal growth factor, tumor necrosis factor alpha (TNF-α), transforming growth factor-beta 1 
(TGF-β1)   and   interleukin-1β   have   been   shown   to   induce   the   transcription of VEGF mRNA 
(Veikkola and Alitalo, 1999). 
2.2.1.3.2 Fibroblast Growth Factor 
First discovered as a family of proteins capable of promoting fibroblast proliferation, 
fibroblast growth factors (FGFs) have been shown to modulate cell proliferation, motility, 
differentiation, and angiogenesis. These molecules are a family of ligands which include twenty-
two members in humans and mice. Often found on the extracellular matrix, these ligands have a 
high affinity for heparin. Depending on the cell-type, FGF signaling can have different effects 
(Dailey et al., 2005). FGF signaling has also been shown to be important in embryonic 
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development in both mouse and human genetics as it orchestrates development by instructing 
uncommitted cells to proliferate and differentiate into specific lineages.  
2.2.1.3.3 Hepatocyte Growth Factor 
Hepatocyte growth factor (HGF) is primarily known for being a growth factor that 
functions in liver regeneration. However, recent evidence shows that HGF is a multipotent growth 
factor involved with regeneration and maintenance of multiple types of tissues and organs. More 
specifically, HGF assists in mitosis for epithelial cells, endothelial cells, stromal cells, and some 
carcinoma cells. It is also involved with hematopoiesis by stimulating the proliferation of 
progenitor cells. HGF can increase cell motility and angiogenesis. Because of this characteristic, 
there is belief that HGF plays a role in tumor cell growth, invasion and metastasis. There is also 
evidence that HGF is involved in chondrogenesis and bone remodeling (Matsumoto and 
Nakamura, 1996). 
One study in particular observed HGF regulation and signaling in hematogenous spreading 
of cancer cells. They found that there was increased HGF expression at both the RNA and protein 
levels, suggesting an important role in promoting epithelial-mesenchymal transition, or cell 
migration (Ogunwobi et al., 2013). In contrast, in human mesenchymal stem cells (hMSCs), HGF 
is down-regulated by the production of transforming growth factor-E. Because of this interaction 
and the production of HGF by activated macrophages, one study notes that HGF production can 
be regulated by the microenvironment. Overall, HGF levels are higher at injured tissue sites (Neuss 
et al., 2004). 
2.2.1.3.4 Transforming Growth Factor 
 Transforming growth factor-beta1 (TGF-E1) is a part of a family of cytokines involved 
with growth and development. Recent studies have shown that macrophages, and B and T 
lymphocytes secrete TGF-E1 (Assoian et al., 1987; Kehrl et al., 1986; Kehrl and Wakefield et al., 
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1986; Chantry et al., 1989). From this, it can be predicted that TGF-E1 also has a role in 
immunoregulation. More specifically, TGF-E1 has a role in the immune system through inhibiting 
various factors such as interleukin expression; B lymphocyte, T lymphocyte, and thymocyte 
proliferation; antibody production; natural killer cell generation, and cytotoxic T cell generation 
(Kehrl and Wakefield et al., 1986; Shalaby and Ammann, 1988; Ellingsworth et al., 1988; Rook 
et al., 1986; Ranges et al., 1987; Chantry et al., 1989) This immunoregulatory function helps 
explain why TGF-E1 can play a significant role in chronic allograft dysfunction. Studies where 
TGF-E1 genes are overexpressed have shown that there is an increased risk of organ rejection after 
transplantation (Pribylova-Hribova et al., 2006). 
2.2.1.3.5 Angiopoietin-1 
 Angiopoietin-1 (ANG1) is a proangiogenic growth factor which has been seen to induce 
distinctive vascular remodeling. Although angiogenic growth factors such as basic fibroblast 
growth factor, vascular endothelial growth factor, and hepatocyte growth factor have been 
explored for ischemia, their ability to promote neovascularization has been outweighed by the 
unwanted side effects of accelerated inflammation and fibrosis. As a result, ANG1 has been 
explored for therapeutic neovascularization. It has been found that systemic or topical application 
of ANG1 accelerates wound closure and epidermal/dermal regeneration through enhanced 
angiogenesis, and increased blood flow in the wound region of db/db diabetic mice (Koh, 2013). 
2.2.1.3.6 Insulin-like Growth Factor 
Insulin-like growth factor (IGF) is a growth factor secreted by many different tissues in the 
body, and thus has different forms. There have been many studies done that connect IGF-I to 
somatic growth and IGF-II to fetal growth (Stewart and Rotwein, 1996). However, it has been 
shown that the functions IGF are determined by the cell secreting it. For instance, IGF-I when 
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secreted from the liver behaves similarly to an endocrine hormone. On the other hand, when being 
secreted by cells such as cartilage cells, it acts as a paracrine hormone. Additionally, there have 
been studies connecting IGF to cancer. When involved with cancer it has been found that the 
growth factor acts in an autocrine manner (Laron, 2001).  
  
2.2.2 Scaffolds 
Biocompatible scaffolds offer a newfound way to enhance the capabilities of stem cells. 
Whether for drug or cell delivery, these scaffolds act as carriers for the treatments. Derived from 
natural sources, natural polymers offer biocompatibility, controlled degradation, and protection 
for the therapy being delivered. Fibrin, alginate, collagen, and chitin are the four commonly used 
natural polymers.  
 Although biomaterials can be derived from various different materials, biocompatibility, 
biodegradability, mechanical properties, surface properties, and manufacturing are all important 
considerations when determining the right biomaterial. For applications of stem cell therapy, tissue 
engineering often requires designing an artificial extracellular matrix to protect and encourage 
attachment and proliferation of cells for in vivo therapies. The recipe for a successful scaffold 
requires proper proportions of balancing mechanical strength with biocompatibility. For 
applications of soft tissues, hydrogels offer high water content, biocompatibility and similar 
mechanical properties. 
 One growing area of interest has been in working to characterize scaffold materials in terms 
of mechanical properties and then observe how cells behave and interact on or within the different 
surfaces. One type of testing which is commonly used for hydrogels is rheometry. Rheometry 
measures the deformation and stress on a material by subjecting it to shear stresses.  
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2.2.2.1 Fibrin 
One biopolymer, fibrin, has been used for numerous stem cell therapies. An important 
component in blood clotting, fibrin monomers form a network of fibers designed for trapping red 
blood cells, leukocytes, and platelets to stop bleeding by forming a stable clot. The polymerization 
process can be seen in Figure 5. By changing certain factors or component concentrations, the 
polymerization dynamics can be modified (Puente and Ludena, 2014).  
 
Figure 5. Formation of a fibrin clot by polymerization (Puente and Ludena, 2014). 
 
For example, changing the catalyst (thrombin) concentration can affect the speed of 
polymerization and branching whereas changing factor XIIIa will affect the degree of crosslinking 
(Brown & Barker, 2014). The use of this polymer has recently been seen in numerous stem cell 
strategies to provide protected targeted delivery. For example, a fibrinogen (3.2%)-fibronectin 
(0.2%)-thrombin hydrogel has previously been studied using autologous lung multipotent stromal 
cells and has helped facilitate 90% LR-MSC survival after four days. However, the strength of this 
engraftment is unknown (Ingenito et al., 2012). 
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 Fibrin is a viscoelastic material with unique mechanical properties. Characterizing elastic 
materials   is   usually   done   using   Hooke’s   law   which   states   that   the   strain   or   deformation   is  
proportional to the stress of force applied per area; however, the stress is independent from the rate 
of   strain.   Viscous   materials   are   characterized   by   Newton’s   law   which   states   that   stress   is  
proportional to the rate of strain but independent from the strain itself. Unfortunately, viscoelastic 
materials such as fibrin are characterized by two different parameters, one for elastic properties 
and the other for the viscous properties. These properties are typically measured by applying a 
known stress and determining the resulting stain based on the distortion of the polymer. Values 
seen before in fibrin gels were 50.85-133 kPa (Ahlfors & Billiar, 2007; Linnes et al., 2007) for 
ultimate tensile strength and 28.56-26.69  KPa  for  Young’s  modulus  (Huang et al., 2010). 
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Chapter 3. Project Strategy 
 After completing a comprehensive literature review, it was well established that there is a 
gap in knowledge regarding how scaffolds affect cell signaling and biomechanics, even though 
cell signaling is important to cell survival, engraftment, and potency. Although previous studies at 
Tufts Cummings School of Veterinary Medicine have used a 3.2%-fibronectin(0.2%)-thrombin 
hydrogel  which showed 90% MSC survival after 4 days, little work has been completed regarding 
how the scaffold environment affects stem cell potency in terms of gene expression. Furthermore, 
the mechanical properties of this fibrin scaffold have not been quantified to determine whether the 
scaffold matches the mechanical properties of the lungs or is even able to withstand the pressures 
seen in the lungs. 
3.1 Initial Client Statement 
 The original client statement was to invent something that could impact the entire field of 
regenerative medicine. The goal was to, develop a scaffold that could: 
(1) Preserve or enhance the potency of signals released by stem cells (including paracrine 
signals and exosomes/'microvesicles') 
(2) Optimize delivery of those signals to adjacent (in contact or not in contact) cells at 
microscalar level 
(3) Have potential for repository function after transplantation (i.e. sponge-like) 
(4) Maintain survival of encapsulated cells for short period after transplantation (i.e. 
protects cell from immediate death or phagocytosis from innate immune system) 
(5) Is safe for delivery into animals/people 
3.2 Revised Client Statement 
 Given the immense undertaking that such a scaffold design would require, along with the 
unknowns as to what determines an ideal scaffold, the client statement was revised to focus on 
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evaluating the effect of scaffold material on stem cell potency in terms of gene expression while 
also ensuring that the mechanical properties of the scaffold mimicked that of healthy lung tissue.   
3.3 Objectives 
  In order to develop an effective scaffold for pulmonary regeneration, a few objectives 
needed to be met. As determined by the team, the scaffold needed to: 
x Be composed of biocompatible & biodegradable material 
x Allow for localized cell delivery 
x Be easy to handle and formulate 
x Maintain or increase gene expression 
x Have similar dynamic compliance to healthy lung tissue 
x Be safe for use in animals and humans 
3.3.1 Ranked Objectives 
 The image below shows a pairwise comparison chart for ranking the previously stated 
objectives. This was completed by the team and Dr. Andrew Hoffman of Tufts Cummings 
Veterinary School of Medicine Regenerative Medicine Laboratory (Figure 6). 
 
Figure 6. Pairwise comparison chart for scaffold objectives. 
3.4 Functions 
 The scaffold also needed to complete numerous tasks. It had to support cell viability and 
growth factor secretion, mimic biomechanic properties of the lung, and maintain or increase gene 
expression levels similar to control MSCs of pre-determined growth factors.  
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3.5 Specifications 
 To be deemed successful, specifications were determined. Experimental groups needed to 
have valid control groups to compare the data. Additionally, a method for preventing cell adhesion 
to the petri dish needed to be completed to prevent invalid data caused by cell adhesion to the 
proteins attached to the petri dish from the media. To encompass the effect of gene expression over 
time, sampling points were specified as 0, 1, 4, 24 and 48 hours. To further investigate the changes 
in gene expression of LR-MSCs, particular genes of interest were chosen based on literature 
findings supporting the importance of these genes. The following seven genes were chosen for 
analysis: VEGFA, ANG1, TGF-B, HGF, FGF7, FGF2 and IGF. Finally, through mechanical 
modeling, the scaffold should show a Young’s  modulus  of  5  kPa  +/- 0.1 kPa which was determined 
by  the  Young’s  modulus  of  a  single  alveolar  wall  (Suki  et  al.,  2005).  
3.6 Constraints 
 The scaffold needed to be developed within a few constraints. First, resources were limited 
to those available and widely used in the Regenerative Medicine Lab at Tufts Cummings School 
of Veterinary Medicine. Specifically, testing was restricted to the available human stem cell lines. 
Since the scaffold is to be used in vivo, it needed to withstand testing at body temperature (37°C). 
Furthermore, to get quality mRNA, a minimum concentration of 0.5x106 cells/mL was required.  
3.7 Project Approach 
 In order to fulfill the goals set forth above, the team considered technical, management, 
and financial aspects. 
3.7.1 Technical 
 To design a biological scaffold which met the criteria outlined above, considerations 
needed to be made regarding designing test methods to effectively characterize the scaffold in 
terms of mechanical parameters and subsequent effects on gene expression. Two separate 
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approaches were used, firstly, gene expression was completed using qPCR and mechanical 
modeling was done based on viscoelastic linear modeling and data seen in previous studies. The 
gene expression studies were done in vitro using LR-MSCS and the scaffold material. To avoid 
adherence as previously addressed as a specification, the control groups were cells suspended in 
media in conical tubes and cells in agar. The studied groups were divided into the experimental 
groups of LR-MSCs within different scaffold concentrations and control groups of LR-MSCs 
alone and LR-MSCs in agar to mimic a 3D environment. 
 For in vitro testing, the scaffold concentration ratio was changed by keeping the fibrinogen 
constant (3 mg/mL) and varying the thrombin concentration. The three experimental groups were 
0.5x, 1x, and 2x which were 500U, 1000U and 2000U thrombin with 3 mg/mL fibrinogen 
respectively. Time points were chosen as t=0 for cells immediately removed from tissue culture 
plastic as a baseline comparison point, t=1, t=4, t=24 and t=48 hours for the experimental and 
control groups. At these points, gene expression was analyzed using qPCR to analyze seven 
carefully chosen targets: VEGFA, HGF, TGF-B1, ANG1, FGF2, FGF7 and IGF. 
3.7.2 Management 
 Time management is key to meeting objectives in an acceptable time frame. The gantt chart 
shown in Figure 7 demonstrates  the  team’s  plan  for  the  project. 
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Figure 7. Basic project timeline for August 2013 to May 2013. 
  
3.7.3 Financial 
 Both materials and methods needed to be evaluated for cost. With a total budget of $468, 
financial considerations needed to be made regarding the cost of materials and methods. Table 1 
below gives an approximate cost analysis for materials and methods. 
 
Table 1. Approximate materials and methods for experiments using the model system. Costs are shown per unit because 
the final cost is dependent upon to number of test required (estimates taken from Sigma Aldrich, Life Technologies, and 
BioTechniques). 
Material Unit Cost per Unit 
Human lung-resident MSCs n/a n/a 
Scaffold n/a n/a 
Fibrinogen 100 mg 50 
Thrombin 1mL 204 
   
Low adherence plates 24 pc 300-350 
Ex-vivo lung n/a n/a 
Method     
PCR n/a 450 
Loading dye n/a 50 
dNTPs 1000 ul 50 
enzyme & buffers n/a 50 
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Primers 1 primer 10 
ethidium bromide 1 gram 40 
TBE buffer 4 liters 50 
Agar 500 g 200 
ELISA 1 kit 500-600 
Western Blots 1 kit 100-200 
Immunochemistry antibody 250-350 
Total - $2304-2654 
 
Exact costs depend on the number of materials and tests needed. Thankfully, most of the project 
costs will be covered by an ongoing grant at Tufts Cummings School of Veterinary Medicine.  
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Chapter 4. Design 
 As previously discussed, fibrin was chosen as the delivery scaffold for human derived LR-
MSCs. Based on the specificity of the design parameters, the concentration of thrombin was 
changed and three experimental groups were used. The groups all contained 3mg/mL fibrinogen 
mixed with either 500 U, 1000 U or 2000 U of thrombin. Prior  to  the  team’s  decision  to  pursue  
fibrin as the ideal biological scaffold, design alternatives were considered.  
4.1 Design Alternatives 
 When generating ideas to address the final client statement, numerous alternative designs 
were proposed. The scaffold material was a huge consideration in designing a new scaffold. Only 
natural biomaterials were considered; such as collagen which is a major extracellular matrix 
component in the lung. However, fibrin was chosen based on its involvement in the coagulation 
cascade during wound healing and based on previous studies supporting the use of fibrin as a 
delivery vehicle for vascularized areas. Altering the material properties by changing the degree of 
crosslinking or branching within polymer scaffolds was also considered as a method to potentially 
create a scaffold which would meet the mechanical properties seen in the lung. Increasing the cell 
density was also proposed to improve the potency of the therapy; however, this was not seen as 
being feasible due to the resulting increase in cost. Likewise, the addition of growth factors such 
as VEGF or HGF could improve the wound healing response in the lung but would be too 
expensive to implicate and choosing one growth factor would be difficult given the thousands of 
cytokines and their diverse functions. 
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Chapter 5. Methodology 
 To evaluate the therapeutic potential of a fibrin scaffold for delivering LR-MSCs, gene 
expression testing and mechanical modeling was completed. The cells in the scaffold (3mg/mL 
fibrinogen and 1000 U thrombin) compared to the cells in agar at 24 hours can be seen in Figure 
8 below. As shown, the cells in the scaffold appear much healthier than the cells in agar because 
they are branching and forming microtubules to form cell-cell interactions. Although the images 
show no viability staining, both of these cells were alive at 24 hours because gene expression was 
completed. 
 
Figure 8. Cells in agar on the left versus cell in the scaffold group with 3mg/mL fibrinogen and 1000 U thrombin on the 
right. 
5.1 Gene Expression 
 Four LR-MSC lines were chosen for gene expression analyses: H1, H2, H4 and H8 (H8 
was run twice, the first run was H8 and the second was H8b). All lines concurrently exhibited 
appropriate tri-lineage differentiation (osteocytes, chondrocytes and adipocyctes when grown in 
differentiation media). Cells at passage 2 were stored in liquid nitrogen, thawed at 37°C and then 
plated on 150mm plates at a density of 500,000 to one million cells per plate. Alpha-MEM 
containing 10-15% Hyclones FBS and 1x Penicillin/Streptomycin/L-glutamine (P/S/L) was used 
as medium, and the plates were maintained in a 37°C incubator with 5% CO2. The medium was 
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changed every 2-3 days until the cells were grown to near-confluence (70-90% confluence) over 
4-6 days. At 12-18 hours prior to scaffold experiments, the FBS-containing medium was removed 
and the plates were washed twice with PBS and serum free medium was applied with 1x P/S/L. 
On the day of the scaffold experiments, the cells were lifted from the plates (passage 3 for the 
scaffold experiments) using Tryp-LE (5mL/plate, incubated at 37°C for 4 minutes, neutralized 
with 10mL serum-free media/PBS). Cell counts were performed manually using Trypan blue 
staining and a hemocytometer (20μl  cell  suspension  and  20μl  Trypan  blue  and  80μl  medium.  Cell  
counts were completed using the formula: Total cells/mL = (#cells in a 4x4 grid)*(6)*(104). One 
cell line was prepared in the above fashion per week. 
5.1.1 Experimental Set-up 
 Scaffold experiments were performed in 6-well plates with one plate per time point and 3 
or 4 plates per cell line (t= 1 hour, 4 hours, 24 hours and 48 hours). The sample placements are 
shown in Figure 9.  Control cells were maintained in 15mL conical polypropylene tubes. 
Fibrinogen was diluted 1:20 with PBS (1 mL full concentration BAC2 mixed with 19mL PBS to 
get a total volume of 20mL). The experimental and control groups were prepared so that they 
contained: 
S0.5x: 62.5 U and 1 mL fibrinogen/cell suspension 
S1x: 125 U and 1mL fibrinogen/cell suspension 
S2x:250 U thrombin and 1 mL fibrinogen/cell suspension 
Agarose: 1 mL 2% agarose/cell suspension 
Cells alone: 1 mL serum-free media/cell suspension 
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Figure 9. Representative image of the 6-well plate set-up. 
 
5.1.2 Scaffold Experimentation 
 The following sequence of events was followed for scaffold experimentation. Thrombin 
was pipetted into three wells per plate as shown in Figure 9 above and was evenly distributed over 
the surface of the well using a sterile spreader. The wells were allowed to dry in the hood. Cells 
were lifted from their plates and counted. Aliquots were separated for resuspension in agarose, 
fibrinogen or conical tubes depending on the group. Cells were then resuspended at one million 
cells/mL in 37°C 2% agarose and aliquots of 1mL were placed in one well of six well plate. Plates 
were wrapped in parafilm and placed within a clean refrigerator (4°C) for 10 minutes to allow the 
agarose to set.  Another aliquot of cells were resuspended at a concentration of one million 
cells/mL in warm (temperature not measured; between room temperature and 37°C) dilute 
fibrinogen. The six-well plates were removed from the refrigerator and one mL of fibrinogen/cell 
suspension was added to each thrombin-coated well. The plates were maintained at 37°C for 15-
30 minutes to allow the scaffolds to polymerize prior to lifting the scaffolds from the bottom of 
the plates (to minimize cells adhering to the plastic of the plate). The cells in agarose could not be 
lifted because they were too delicate. Five mL of serum-free media was added to each well 
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containing the scaffold and agarose. Aliquots of one million cells were separated into 15 mL 
polypropylene tubes and brought to a total volume of one mL with serum-free media.  
For cell lines H2 and H8b, an additional test was run using aliquots of cells to observe 
whether the cells in media alone would behave differently if they were spread over a large surface 
area. For H2 cells, plates were prepared by coating each well with dextran to minimize binding 
(one million cells were placed in each of the wells in one mL of media and treated the same as the 
cell suspensions). For H8b cells, one million cells were placed within the flat polypropylene caps 
of the 50mL conical tubes and these caps were then placed in a large petri dish. 
5.1.3 RNA Sample Preparation 
 At each time point, the same procedure was followed for each group within each cell line. 
For the experimental groups, the scaffolds were gently removed from their wells and placed into 
labeled 50 mL conical polypropylene tubes with efforts to minimize the amount of media taken 
with the sample. However, for 48 hour scaffolds, most of the mechanical integrity had been broken 
down so the entire scaffold could not be simply lifted from the tubes. As a result, the full contents 
of the wells were collected in 15 mL conical tubes and centrifuged (1500 rpm for five minutes). 
The supernatant was then removed and the cell pellet was resuspended in Trizol for RNA 
extraction. For the agarose well, media was gently aspirated from the well using manual pipetting 
and the gel was then moved into a 50 mL conical polypropylene tube for processing. Trizol (Life 
Technologies, Cat. No. 15596), was added to each sample in the following volumes: 2.5mL Trizol 
to all intact scaffold groups, 2.5mL Trizol to non-intact  scaffold  “pellet”  groups,  2.0mL  Trizol  to  
the 1 mL cell suspension, 2.5mL Trizol to the agarose groups and 0.5mL Trizol to the t=0 baseline 
samples which were only 100-200µL total volume of cells suspensions. All samples were 
incubated with Trizol for approximately 30 minutes. Following incubation, homogenization (using 
a disposable homogenizer) was performed on all scaffold and agarose samples. Control cell 
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suspensions were briskly pipetted and agitated but not homogenized. The samples were either 
immediately processed for RNA extraction of frozen at -80°C until processing.   
5.1.4 RNA Extraction 
 Chloroform was added to each Trizol sample at a volume of 100µL for each 500µL of 
Trizol sample. RNA extraction was completed as directed by the Life Technologies Trizol Reagent 
Total RNA Isolation Reagent Protocol. Following RNA extraction, the RNA samples were quality 
tested using standard protocols and then frozen at -20°C until qPCR (see Appendix B for quality 
data). Note that only RIN values over 8 were considered acceptable for processing with qPCR. 
5.1.5 qPCR  
 cDNA was synthesized and PCR was performed using standard protocols (see Appendix 
A). For PCR analysis, the following primers were used, GAPDH (housekeeping gene), TGFB, 
VEGFA, HGF, IGF, FGF2, FGF7 and ANGPT1. cDNA preparation yielded a total volume of 
20µL; 110 µL RNAse-free H20 was added to each cDNA sample to reach a total volume of 130µL 
and to allow for 24 five µL samples (three replicates for each of the eight primers).   
 
5.2 Mechanical Modeling 
 Predicting the mechanical properties of fibrin when the thrombin concentration is changed 
was completed based on literature which has previously testing fibrin. The data correlation and 
calculations will be addressed further in the results and discussion section. 
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Chapter 6. Results and Discussion 
6.1 Gene Expression 
 The results herein are from the H1 LR-MSC line. All other cell lines results can be found 
in Appendix C. 
6.1.1 Compared to Baseline 
 To quantify the changes in gene expression between baseline (t=0) LR-MSCs to the LR-
MSCs placed within the scaffold, RNA was isolated from both batches of cells, and RT-PCR was 
performed on seven carefully chosen targets plus a GAPDH housekeeping gene. Three graphs 
show the fold changes from baseline (no scaffold) relative to three scaffold groups, from 1 to 24 
hours (Figures 10 to 12). 
 
Figure 10. Fold change in gene expression for baseline and 0.5x scaffold group over time.  
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Figure 11. Fold change in gene expression for baseline and 1x scaffold group over time 
 
Figure 12. Fold change in gene expression for baseline and 2x scaffold group over time. 
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 For all three scaffolds, FGF-2 showed an apparent decrease in expression at 4 hours, which 
returns to baseline at 24 hours. TGFB, IGF, and ANG1 showed no major changes from the baseline 
group at any time tested. All three scaffolds appear to reduce the expression of VEGFA by 24 
hours, and appeared to increase the levels of ANG1 by 24 hours. 
 The fold changes for each sample are shown in Table 2.  Results are shown only for the 
changes between the control group of freely suspended cells in media (no scaffold) and the three 
different scaffold groups. Unfortunately, quality RNA was not obtained for all of the agar control 
groups so the few agar RNA results will not be discussed here. 
Table 2. The fold changes in gene expression relative to the control LR-MSCs freely suspended in media are shown over 
time at 1, 4 and 24 hours. Targets showing the greatest fold up or down regulation are bolded. 
  Fold Change from Control 
Time (hours) Gene 0.5x Scaffold 1x Scaffold 2x Scaffold 
1 
TGFB 3.56 2.28 1.97 
VEGFA 2.87 2.64 2.35 
FGF2 -1.20 -1.23 -1.52 
FGF7 -2.59 -1.79 -2.22 
HGF 1.18 1.17 -1.15 
IGF -1.04 -1.07 -1.41 
ANG1 -2.06 -1.57 -2.57 
4 
TGFB 2.09 2.06 2.06 
VEGFA 1.85 2.31 1.88 
FGF2 -3.12 -3.07 -3.92 
FGF7 -7.16 -7.26 -11.88 
HGF -2.81 -2.53 -4.82 
IGF -5.74 -4.66 -7.73 
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ANG1 -3.39 -4.14 -6.36 
24 
TGFB 3.81 6.41 5.09 
VEGFA -3.56 -2.41 -2.66 
FGF2 -2.79 -1.97 -2.89 
FGF7 -21.11 -20.97 -29.04 
HGF -1.83 -1.83 -2.51 
IGF -2.79 -2.30 -1.16 
ANG1 2.24 1.52 1.40 
 
6.1.2 Compared to Control 
To further examine the gene expression within the control and experimental groups at each 
time point, data from the same experiment in Figures 13-15 show gene expression at t=1, t=4 and 
t=24 hours respectively (error bars were not included in the histograms because the standard 
deviation was very low). 
 
Figure 13. Gene expression at one hour for the control and experimental groups. 
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Figure 14. Gene expression at four hours for the control and experimental groups. 
 
 
Figure 15. Gene expression at 24 hours for the control and experimental groups. 
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Figure 15 indicates that of the seven genes assessed for gene expression levels, TGFB and 
ANG1 in each experimental scaffold are unregulated from the control group after 24 hours. 
Figures 13-15 show maintained expression levels of TGFB and increased expression levels of 
ANG1 overtime, thus ANG1 was chosen as a representative gene for comparing the three scaffold 
groups. 
A statistical analysis was completed to determine whether any of the apparent fold changes 
from the control were significant for any of the scaffolds at 24 hours (Table 3).  VEGFA, FGF2, 
and FGF7 all showed significant changes in gene expression (p<0.05) at 24 hours. 
Table 3. Statistical significance between three different scaffold groups and the control without scaffold at 24 hours for 
each gene. 
 
 
Table 3 above does not give statistical differences; however, statistical significance was completed 
and only showed significant up regulation of TGF-B and ANG1 in the scaffold groups and 
significant down regulation for all of the remaining genes with the exception of IGF in the 2x 
scaffold (not bold). 
6.1.3 ANG1 
 Based on the findings in gene expression for baseline and control groups compared to the 
scaffolds, ANG1 was chosen to further observe changes in the up or down regulation of this gene. 
To further emphasize the amplitude of change seen in ANG1 over time, Table 4 below shows the 
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fold change for each of the six genes compared to ANG1 at 24 hours as well as the statistical 
difference between gene expression for each gene and ANG1 at 24 hours. Based on this table, it is 
evident that ANG1 showed a dramatic fold change compared to other genes which showed little 
change at 24 hours. Furthermore, this is supported by the fact that there is a statistical difference 
between gene expression for each gene and ANG1 at 24 hours. 
Table 4. Fold change between ANG1 and the other genes for the experimental and control group as well as statistical 
significance between the gene expression of ANG1 and the six other genes at 24 hours. 
Fold Change from ANG1 
 0.5x 1x 2x Control Statistical Difference from ANG1 
TGFB -18.90 -7.62 -8.88 -32.22 0.007 
VEGFA -744.43 -342.51 -349.71 -93.70 0.001 
FGF2 -330.84 -158.68 -215.27 -53.08 0.001 
FGF7 -166.57 -112.21 -144.01 -3.53 0.000 
HGF -39.95 -27.10 -34.54 -9.78 0.001 
IGF 11.16 19.97 42.81 69.55 0.008 
 
The change in ANG1 expression over time can be seen in Figure 16 below where the control is 
cells in media and t=0 is the baseline ANG1 expression. 
 
Figure 16. ANG1 expression over time for the baseline, control and experimental groups. 
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All three of the scaffold groups were significantly unregulated from the baseline group 
after 24 hours and from the control cells at 24 hours. The 0.5x scaffold showed significant up 
regulation of ANG1 when compared to the 1x and 2x scaffold groups. With ANG1 as a 
representative gene that shows unregulated expression levels in the scaffold groups after 24 hours, 
Figure 16 implies that the 0.5x scaffold is optimal for this in vivo treatment. 
6.1.4 Limitations 
Unfortunately, the two experimental groups used to evaluate the binding efficiency and 
effects of cells alone did not result in usable RNA samples. For the H2e cells, very low RNA yields 
were obtained due to excessive cell binding which indicated that the dextran was not an effective 
treatment to keep cells in suspension. Likewise, the H8b cells kept in the polypropylene caps had 
poor recovery, possibly due to the binding of the cells to the caps. Some general observations made 
throughout experimentation were that at 4 hours and definitely by 24 hours, the cells within the 
scaffold adopted a typical  “MSC”  appearance  (spreading  could  be  seen  as  demonstrated  in  Figure 
8 above). In contrast, the cells within the agarose remained rounded and showed no signs of 
spreading or obvious migration over the entire experiment. Furthermore, RNA extraction from the 
agarose gave a lower yield than cells alone or cells within the scaffolds. It is expected that this 
could possibly be due to agarose binding to the RNA during the extraction or potentially decreased 
RNA production by the cells themselves.  
 
6.2 Mechanical Modeling 
 Based on previous research involving the pressures, forces, and elasticity values associated 
with the lung it was found that the maximum forces in the at total lung capacity are 7.68 N, the 
maximum pressure is 8 kPa, and the elastic modulus for a single alveolus is approximately 5 kPa 
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(Hoehm and Marieb, 2013, Suki et al., 2005). In order to determine if the fibrin scaffold is both 
strong enough and flexible enough to withstand these values, mechanical modeling was done using 
data from Benkherourou and colleagues. Figure 17, below, shows the resulting stress relaxation 
curve from a 30 Pm strain step on a 3 mg/mL fibrin scaffold (Benkerourou, 2000).  
 
 
Figure 17. Stress relaxation curve of 3 mg/mL fibrin scaffold as a response to 30 µm step in strain (Benkerourou, 2000). 
 
 Using this data and standard linear solid viscoelastic modeling, elastic moduli and the 
viscosity coefficient of the scaffold could be predicted. The original size of the scaffold in the 
current study has an area of 9.600 cm2, therefore, has a diameter of 3.496 cm. According to the 
definition of strain in Eq. 1, the 30 Pm step in strain would cause a strain of 85.81x10-3. 
 
𝜀 = ௅ି௅೚௅೚   (Eq. 1) 
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Where L is equal to the final length after strain (0.03496 m), and Lo is the original length of the 
specimen (0.03499 m). Therefore the strain percentage change is 0.08581%.  
 Linear elastic models of a viscoelastic solid are represented by the equation shown in Eq. 
2.  
 
𝜎(𝑡) = 𝜀௢
ாభாమ
ாభାாమ
[1 + ாభாమ 𝑒
ିቀಶభశಶమആ ቁ௧]   (Eq. 2) 
 
Evaluating this relationship when t is equal to 0 seconds, infinity, and a time constant (W), reveals 
the elastic moduli (E1 and E2) and the viscoelastic constant (K). To first manipulate the relationship, 
t is equal to 0 seconds. This yields the equation shown in Eq. 3.  
 
𝜎(0) = 𝜀௢
ாభாమ
ாభାாమ
ቂ1 + ாభாమቃ = 𝜀௢𝐸ଵ   (Eq. 3) 
 
At this point the group was able to solve for E1, by taking the peak stress from the graph in Figure 
17 to be 32.50 Pa. E1 was equal to 378.7 Pa. 
 Taking this value and manipulating Eq. 2 at time equals infinity to reveal Eq. 4 allowed the 
group to next solve for E2. 
 
𝜎(∞) = 𝜀௢
ாభாమ
ாభାாమ
  (Eq. 4) 
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The stress at time infinity according to the data in Figure 17 is 20 Pa. This yielded a value of 606.1 
Pa for E2. 
 Finally, Eq. 2 was manipulated to solve for K. In order to do this the exponential portion of 
the equation needed to be first set equal to -1 to find the time constant, W. This first manipulation 
is shown in Eq. 5. 
 
𝜎(𝜏) = 𝜀௢
ாభாమ
ாభାாమ
[1 + ாభாమ 𝑒
ିଵ]   (Eq. 5) 
 
This calculation revealed that at W, the stress was equal to 24.61 Pa. Referring back to the original 
data, a value of 24.61 Pa occurs at approximately 200 seconds. Using these values in Eq. 6 revealed 
the value of the viscosity.  
 
𝜂 = (𝐸ଵ + 𝐸ଶ)𝑡   (Eq. 6) 
 
When t is equal to 200 seconds, the viscosity coefficient is equal to 197.0 kPa*s.  
 After  determining  the  Young’s  moduli  and  the  viscosity  of  the  original  3  mg/mL  fibrinogen 
scaffold (with 1000 U of thrombin), the group expects that increasing or decreasing thrombin 
concentration will cause the mechanical properties to change. Since the thrombin concentration 
will determine the rate at which polymerization occurs and the degree of branching within the 
polymer, the group predicts that the more thrombin included in the scaffold will result in longer, 
more intertwined polymers of fibrin. Therefore, more crossing over between polymers will cause 
more strength in the scaffold. Additionally, since the raw data from Benkherourou et al. (2000) 
originates from a scaffold from a much smaller size scale, the group predicts that a larger strain 
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step will also increase the resulting mechanical parameters. Overall, the group predicts that these 
changes in the scaffold properties would also cause the viscosity coefficient to increase. In order 
to demonstrate this future rheological testing must be done.  
6.3 General Findings 
The development of this fibrin scaffold has the potential to influence many individuals as 
well as populations alike in areas such as health and safety, economics, sustainability, and politics. 
Overall,   the  group  hopes  that  since  the  product   is  created  for  the  individual’s  wellbeing,   larger  
scale impacts like global market and economics will be minimal or at least beneficial. In terms of 
a microeconomic standpoint, the group expects that the scaffold will benefit those with COPD in 
a sense that they will not have to pay for extensive surgery or life-long medications. The scaffold 
will allow patients to have one procedure to insert the scaffold into the lungs, and then potentially 
be on temporary antibiotics in order to ensure no infection occurs due to the surgery. We cannot 
predict the cost of this regenerative approach at this time but we do expect it will still be costly 
simply because of the time and complexity involved in deriving LR-MSCs from each individual 
to create this personalized treatment. However, in the long run, this therapy will  better  the  patient’s  
everyday living because they do not have to worry about future medical bills due to complications 
or rejection of lung transplants. 
On the other hand, the group expects that this scaffold could potentially have a negative 
effect on political ramifications. While it is expected that this therapy could have potential to be 
slightly cheaper than a full lung transplant, until the procedure is finalized and made more efficient, 
there is the distinct possibility that developing countries may not be able to afford the therapy. This 
impact may also be related to a societal impact in areas that have a middle or lower class economy. 
The group hopes that after further testing, a more cost efficient method of growing and obtaining 
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mesenchymal stem cells will allow this therapy to be available for people in a lower income 
bracket. Furthermore, these implications may also be related to the manufacturability of the 
product. Fibrin, made of fibrinogen and thrombin, is readily available as well as FDA approved 
(Evicell by Johnson & Johnson). Therefore, the manufacturing of the actual scaffold should not be 
problematic. If any problems arise with manufacturing it would be involving the mesenchymal 
stem cells. This is because the cells not only need to be obtained, but need to be grown substantially 
as  well.  This  causes  the  product  to  be  less  easily  an  “off-the-shelf”  type  of  product.  More  efficient  
cell growth techniques would need to be developed to decrease the chance of this issue. 
In terms of the environment, the overall scope of the project should not have great positive 
or negative impacts. The scaffold will not be implemented anywhere other than the individual 
person; therefore, there will not be direct interaction between the environment and this therapy. 
Likewise, in terms of sustainability, this project would not affect biology or ecology in terms of 
renewable energy. 
Finally, as with any health related products there are ethical considerations and health and 
safety concerns. Since stem cells are used in conjunction with the developed scaffold, the ethical 
concern is raised about whether or not stem cells should be used since they are derived from human 
tissue. In the case of mesenchymal stem cells, they can be developed from any human stromal 
tissue, therefore we are hoping the availability will limit the ethical concern. Health and safety will 
likely have positive impacts from the development of this scaffold since the aim of the project is 
to improve the health of patients with COPD. With using cells as well as a biological scaffold, 
there is the risk of having a negative immune response. The group hopes that using human derived 
MSCs will minimize this response. Also, since fibrin is a major component of blood clotting the 
group hopes that the immune system will not recognize the scaffold as a foreign body.  
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Chapter 7. Conclusion 
Based on the results from gene expression, if the 0.5x scaffold can withstand the mechanical 
forces seen in the alveoli environment, this scaffold concentration should be explored further to 
determine whether it is can withstand the dynamic compliance seen in the lung. Although the 0.5x 
scaffold has shown promise in upregulating ANG1 after 24 hours, increases in mRNA expression 
do not necessarily correlate with an increase of functional protein release; therefore, future studies 
using transwells to observe protein release through the scaffold to a secondary cell line need to be 
done. Finally, to validate the mechanical modeling, rheology should be used to test various fibrin 
scaffolds with and without cells. 
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Chapter 8. Future Recommendations 
 Although the study showed promising results regarding the potential for this therapy in 
vivo, additional testing should be completed. To validate whether changes in gene expression 
resulted in functional protein release, a test method for using transwells to see the potency effect 
of LR-MSCs within scaffold groups on a secondary cell line such as endothelial cells would be 
useful. This type of proposed system can be seen in Figure 18.  
 
Figure 18. The transwell set-up using two separated cell lines with a reservoir of media to nourish the cells and allow for 
exchange of extracellular vesicles or signals. The porous membrane should be optimized to allow for signal exchange but 
not for cell migration. 
 Analysis of the secondary cell line in terms of viability and proliferation should be 
completed to determine whether the changes in gene expression of LR-MSCs have a strong 
influence on the fate of endothelial cells. Ideally, the growth factors should promote endothelial 
cell survival and proliferation. Alternative studies simply using western blots to analyze protein 
release from the scaffold with cells could also be completed. 
 In  order  to  demonstrate  the  group’s  prediction  about  the  effect  of  thrombin  on  mechanical  
properties of the scaffold, the group would continue testing through rheology. Based on a study by 
Wedgwood (2013), stress amplitude tests and frequency sweep tests would be combined to obtain 
more accurate values of the mechanical parameters outlined in the mechanical modeling section 
(Wedgwood, 2013). Through this testing, the group would expect to obtain additional parameters 
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such as the loss modulus, storage modulus, and complex viscosity. Based off of the results of this 
testing, it is predicted that these mechanical parameters will be able to more accurately match the 
scaffold with a viscosity model, while also showing the relationship between viscosity and 
thrombin concentration. Furthermore, knowing these relationships, the group expects to better 
validate the composition of the final scaffold.  
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Appendix A: Protocols 
qRT-PCR (RT2 SYBER Green Mastermix) 
1. Need 5 uL of cDNA per reaction so enough RNAse free water was added to ensure that 
there was enough cDNA for the reaction 
2. Reaction mix (per sample): 
RT Mastermix: 12.5 uL 
Water: 6.5 uL 
Primer Mix (10 uM each): 1 uL 
3. Add 20 uL of the reaction mix to each sample with 5 uL of the cDNA to reach a total 
volume of 25uL reaction volume 
4. Add either caps or tape to seal plate 
5. Spin PCR plate down briefly before placing into machine for analysis 
6. Place into machine for analysis 
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Appendix B: RNA Quality 
Table 5. RNA quality for H1 cell line. Although RIN values were not retrieved for rows 8-10 and the quality for rows 14 
& 15 was 7.7, the samples were still processed using qPCR and gene expression was seen. 
H1 RIN Conc (ng/uL) RNA (1000ng) H2O 
1 T0 cells 8.8 470 2.1 5.9 
2 T1 cells 8.8 417 2.4 5.6 
3 T1 S0.5x 8.7 306 3.3 4.7 
4 T1 S1x 8.8 351 2.8 5.2 
5 T1 S2x 8.6 328 3.0 5.0 
6 T1 Ag 9.2 76 - - 
7 T4 cells 8.7 529 1.9 6.1 
8 T4 S0.5x - 377 2.7 5.3 
9 T4 S1x - 333 3.0 5.0 
10 T4 S2x - 305 3.3 4.7 
11 T4 Ag 9.6 205 4.9 3.1 
12 T24 cells 8.1 147 6.8 1.2 
13 T24 S0.5x 8.0 146 6.8 1.1 
14 T24 S1x 7.7 145 6.9 1.1 
15 T24 S2x 7.7 158 6.3 1.7 
16 T24 Ag 9.2 73 - - 
17 T48 cells 4.2 20 - - 
18 T48 S0.5x 8.1 107 - - 
1 T48 S1x 7.6 147 6.8 1.2 
20 T48 S2x 7.8 81 - - 
21 T48 Ag 8.1 32 - - 
 
Table 6. RNA quality for H2 cell line. Note that the cells w/d stands for the control group of cells on plates coated with 
dextran. 
H2 RIN Conc (ng/uL) RNA (1000ng) H2O 
1 T0 cells 9.3 423 2.4 5.6 
2 T1 cells 9.1 371 2.7 5.3 
3 T1 cells w/d - 9 - - 
4 T1 S0.5x 9.8 265 3.8 4.2 
5 T1 S1x 9.7 256 3.9 4.1 
6 T1 S2x 9.5 309 3.2 4.8 
7 T1 Ag 9.7 144 6.9 1.1 
8 T4 cells 9.0 370 2.7 5.3 
9 T4 cells w/ d 8.4 28 - - 
10 T4 S0.5x 9.4 286 3.5 4.5 
11 T4 S1x 9.6 316 3.2 4.8 
12 T4 S2x 9.3 268 3.7 4.3 
13 T4 Ag 9.4 203 4.9 3.1 
14 T24 cells 8.8 388 2.6 5.4 
15 T24 cells w/ d 9.0 155 6.5 1.5 
16 T24 S0.5x - 247 4.0 4.0 
17 T24 S1x - 167 6.0 2.0 
18 T24 S2x - 151 6.6 1.4 
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1 T24 Ag 9.1 55 - - 
20 T48 cells 4.4 46 - - 
21 T48 cells w/ d 4.4 18 - - 
22 T48 S0.5x 6.9 133 7.5 0.5 
23 T48 S1x 7.3 76 - - 
24 T48 S2x 8.7 144 6.9 1.1 
25 T48 Ag - 5 - - 
 
Table 7. RNA quality for H4 cell line.  
H4 RIN Conc (ng/uL) RNA 
(1000ng) 
H2O 
1 T0 cells 9.9 468 2.1 5.9 
2 T1 cells 9.7 488 2.0 6.0 
3 T1 S0.5x 10 278 3.6 4.4 
4 T1 S1x 10 523 1.9 6.1 
5 T1 S2x 9.9 331 3.0 5.0 
6 T1 Ag 9.7 15 - - 
7 T4 cells 9.5 566 1.8 6.2 
8 T4 S0.5x 10 405 2.5 5.5 
9 T4 S1x 9.9 397 2.5 5.5 
10 T4 S2x 10 325 3.1 4.9 
11 T4 Ag 9.7 20 - - 
12 T24 cells 9.1 302 3.3 4.7 
13 T24 S0.5x - 235 4.3 3.7 
14 T24 S1x - 86 - - 
15 T24 S2x - 296 3.4 4.6 
16 T24 Ag 9.9 33 - - 
17 T48 cells 4.9 40 - - 
18 T48 S0.5x - 442 2.3 5.7 
19 T48 S1x - 356 2.8 5.2 
20 T48 S2x - 148 6.8 1.2 
21 T48 Ag - 10 - - 
 
Table 8. RNA quality for H8 cell line 
H8 RIN Conc (ng/uL) RNA (1000ng) H2O 
1 T0 cells 9.3 710 1.4 6.6 
2 T1 S0.5x 10 681 1.5 6.5 
3 T1 S1x 10 741 1.3 6.7 
4 T1 S2x 10 775 1.3 6.7 
5 T1 Ag 9.6 489 2.0 6.0 
6 T4 S0.5x 9.2 686 1.5 6.5 
7 T4 S1x 9.5 587 1.7 6.3 
8 T4 S2x - 297 3.4 4.6 
9 T4 Ag 9.7 260 3.8 4.2 
10 T24 S0.5x - 219 4.6 3.4 
11 T24 S1x - 384 2.6 5.4 
12 T24 S2x - 289 3.5 4.5 
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13 T24 Ag 9.5 86 - - 
 
Table 9. RNA quality  for  H8b  cell  line.  Note  that  the  “cells  cap”  groups  were  the  control  groups  cultured  on  the  
polypropylene caps.  
H8b RIN Conc (ng/uL) RNA (1000ng) H2O 
1 T0 cells 9.3 371 2.7 5.3 
2 T1 cells 9.3 352 2.8 5.2 
3 T1 cells cap - 18 - - 
4 T1 S0.5x 9.7 188 5.3 2.7 
5 T1 S1x 9.7 214 4.7 3.3 
6 T1 S2x 9.5 223 4.5 3.5 
7 T1 Ag 9.8 156 6.4 1.6 
8 T4 cells 9.0 332 3.0 5.0 
9 T4 cells cap - 3 - - 
10 T4 S0.5x 9.8 174 5.7 2.3 
11 T4 S1x 9.9 182 5.5 2.5 
12 T4 S2x 9.9 318 3.2 4.8 
13 T4 Ag 9.3 226 4.4 3.6 
14 T24 cells 8.7 186 5.4 2.6 
15 T24 cells cap - 4 - - 
16 T24 0.5x  - 125 8.0 0.0 
17 T24 S1x - 106 - - 
18 T24 S2x - 132 7.6 0.4 
19 T24 Ag 9.4 28 - - 
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Appendix C: Gene Expression Results 
H2 
Compared to Baseline 
Table 10. H2 cells: Statistical significance of gene expression between each scaffold group and the baseline for each gene. 
  0.5x 1x 2x 
TGFB 0.378 0.329 0.463 
VEGFA 0.025 0.068 0.036 
FGF2 0.131 0.215 0.126 
FGF7 0.270 0.455 0.211 
HGF 0.126 0.284 0.128 
IGF 0.210 0.151 0.217 
ANG1 0.240 0.173 0.196 
 
 
Figure 19. Fold change in gene expression of H2 cells for baseline and 0.5x scaffold group over time.  
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Figure 20. Fold change in gene expression of H2 cells for baseline and 1x scaffold group over time.  
 
 
Figure 21. Fold change in gene expression of H2 cells for baseline and 2x scaffold group over time. 
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Compared to Control 
Table 11. The fold changes in gene expression relative to the control H2 LR-MSCs freely suspended in media are shown 
over time at 1, 4 and 24 hours. 
  Fold Change from Control 
Time (hours) Gene 0.5x Scaffold 1x Scaffold 2x Scaffold 
1 
TGFB n/a 1.61 1.40 
VEGFA n/a 2.30 1.43 
FGF2 n/a -1.80 -2.33 
FGF7 n/a -2.19 -2.43 
HGF n/a -1.49 -2.10 
IGF n/a -2.57 -3.41 
ANG1 n/a -1.83 -2.41 
4 
TGFB 1.43 1.23 1.24 
VEGFA 1.02 -1.05 -1.14 
FGF2 -2.85 -2.41 -2.62 
FGF7 -4.63 -4.72 -6.06 
HGF -2.64 -2.89 -2.81 
IGF -7.94 -10.06 -10.93 
ANG1 -4.17 -4.76 -4.82 
24 
TGFB 2.45 2.68 1.97 
VEGFA -2.16 -2.48 -2.83 
FGF2 -4.66 -3.39 -4.47 
FGF7 -27.47 -17.75 -25.81 
HGF -10.20 -9.65 -9.58 
IGF -23.26 -17.39 -11.71 
ANG1 -2.66 -2.03 -1.28 
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Figure 22. Gene expression at one hour for the experimental groups for H2 cell line. Note that quality RNA could not be 
achieved for the control group. 
 
 
Figure 23. Gene expression at four hours for the control and experimental groups for H2 cell line. 
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Figure 24. Gene expression at 24 hours for the control and experimental groups for H2 cell line. 
H4 
Compared to Baseline 
Table 12. H4 cells: Statistical significance of gene expression between each scaffold group and the baseline for each gene. 
  0.5x 1x 2x 
TGFB 0.150 0.056 0.145 
VEGFA 0.095 0.163 0.115 
FGF2 0.050 0.140 0.077 
FGF7 0.128 0.219 0.049 
HGF 0.077 0.112 0.061 
IGF 0.297 0.037 0.099 
ANG1 0.352 0.415 0.224 
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Figure 25. Fold change in gene expression of H4 cells for baseline and 0.5x scaffold group over time. 
 
 
Figure 26. Fold change in gene expression of H4 cells for baseline and 1x scaffold group over time.  
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Figure 27. Fold change in gene expression of H4 cells for baseline and 2x scaffold group over time. 
 
Compared to Control 
Table 13. The fold changes in gene expression relative to the control H4 LR-MSCs freely suspended in media are shown 
over time at 1, 4 and 24 hours. 
  Fold Change from Control 
Time (hours) Gene 0.5x Scaffold 1x Scaffold 2x Scaffold 
1 
TGFB 1.79 1.51 1.65 
VEGFA 1.22 2.31 1.92 
FGF2 -1.78 -1.27 -1.78 
FGF7 -2.35 -1.83 -1.45 
HGF -1.32 -1.05 -1.37 
IGF -1.66 -1.48 -1.87 
ANG1 -2.11 -1.53 1.97 
4 
TGFB 1.91 1.18 1.28 
VEGFA 3.73 2.99 1.97 
FGF2 -2.93 -3.73 -3.94 
FGF7 -3.12 -2.11 -6.15 
HGF -1.21 -1.43 -1.41 
IGF -2.13 -4.86 -5.13 
ANG1 1.11 -2.39 -3.48 
24 
TGFB 1.38 1.33 1.92 
VEGFA -2.38 -2.69 -3.89 
FGF2 -13.18 -9.38 -9.71 
FGF7 -56.89 -46.53 -24.08 
HGF -10.93 -12.38 -9.19 
IGF -73.52 -45.89 -26.17 
ANG1 -19.97 -14.93 -9.85 
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Figure 28. Gene expression at one hour for the control and experimental groups for H4 cell lines. 
 
 
Figure 29. Gene expression at four hours for the control and experimental groups for H4 cell line. 
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Figure 30. Gene expression at 24 hours for the control and experimental groups for H4 cell line. 
H8 
Compared to Baseline 
Table 14. H8 cells: Statistical significance of gene expression between each scaffold group and the baseline for each gene. 
  0.5x 1x 2x 
TGFB 0.091 0.029 0.019 
VEGFA 0.017 0.025 0.019 
FGF2 0.016 0.015 0.015 
FGF7 0.001 0.004 0.005 
HGF 0.011 0.020 0.018 
IGF 0.029 0.011 0.017 
ANG1 0.104 0.094 0.114 
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Figure 31. Fold change in gene expression of H8 cells for baseline and 0.5x scaffold group over time. 
 
 
Figure 32. Fold change in gene expression of H8 cells for baseline and 1x scaffold group over time 
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Figure 33. Fold change in gene expression of H8 cells for baseline and 2x scaffold group over time 
 
Compared to Control 
 RNA could not be retrieved from the control groups because there were not enough cells 
left to run the experiments which resulted in the inability to get quality mRNA. 
 
Figure 34. Gene expression at one hour for the control and experimental groups for H4 cell line. 
66 
 
 
Figure 35. Gene expression at 4 hours for the control and experimental groups for H8 cell line. 
 
Figure 36. Gene expression at 24 hours for the control and experimental groups for H8 cell line. 
